Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate J Dixon

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancers|January 20, 2021
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK CellsKate J Dixon, Jianming Wu, Bruce Walcheck
Frontiers in Immunology|August 9, 2021
Activation of ADAM17 by IL-15 Limits Human NK Cell ProliferationHemant K Mishra, Kate J Dixon, Nabendu Pore, et al.
Frontiers in Immunology|June 13, 2018
IQ Domain-Containing GTPase-Activating Protein 1 Regulates Cytoskeletal Reorganization and Facilitates NKG2D-Mediated Mechanistic Target of Rapamycin Complex 1 Activation and Cytokine Gene Translation in Natural Killer CellsAlex M Abel, Aradhana A Tiwari, Zachary J Gerbec, et al.
Frontiers in Immunology|February 16, 2026
Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicityKate J Dixon, Robert Hullsiek, Sam Wang, et al.
Molecular Immunology|July 9, 2021
MyD88 is an essential regulator of NK cell-mediated clearance of MCMV infectionKate J Dixon, Jason R Siebert, Dandan Wang, et al.
Journal for Immunotherapy of Cancer|December 6, 2023
iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targetingKristin M Snyder, Kate J Dixon, Zachary Davis, et al.
Frontiers in Immunology|August 5, 2024
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphomaKate J Dixon, Kristin M Snyder, Melissa Khaw, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob Hullsiek, Kate J Dixon, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob H Hullsiek, Kate J Dixon, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancers|January 20, 2021
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK CellsKate J Dixon, Jianming Wu, Bruce Walcheck
Frontiers in Immunology|August 9, 2021
Activation of ADAM17 by IL-15 Limits Human NK Cell ProliferationHemant K Mishra, Kate J Dixon, Nabendu Pore, et al.
Frontiers in Immunology|June 13, 2018
IQ Domain-Containing GTPase-Activating Protein 1 Regulates Cytoskeletal Reorganization and Facilitates NKG2D-Mediated Mechanistic Target of Rapamycin Complex 1 Activation and Cytokine Gene Translation in Natural Killer CellsAlex M Abel, Aradhana A Tiwari, Zachary J Gerbec, et al.
Frontiers in Immunology|February 16, 2026
Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicityKate J Dixon, Robert Hullsiek, Sam Wang, et al.
Molecular Immunology|July 9, 2021
MyD88 is an essential regulator of NK cell-mediated clearance of MCMV infectionKate J Dixon, Jason R Siebert, Dandan Wang, et al.
Journal for Immunotherapy of Cancer|December 6, 2023
iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targetingKristin M Snyder, Kate J Dixon, Zachary Davis, et al.
Frontiers in Immunology|August 5, 2024
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphomaKate J Dixon, Kristin M Snyder, Melissa Khaw, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob Hullsiek, Kate J Dixon, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob H Hullsiek, Kate J Dixon, et al.
Pageof 1